Fresh analysis indicates that people who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional lifestyle plans.
Research printed in a leading medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Individuals buying such treatments must be aware of the potential of quick weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass within about 18 months.
Weighing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of participants, contrasted the outcomes of the injectable medications with other pills.
The team note that people who shed pounds through diet and exercise usually have a slower weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Regain
Experts suggest the mode of action of the drugs accounts for the heightened rebound.
These medications imitate a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this medication means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Health authorities suggest the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, given the high risk of relapse, the therapy might need to be long-term.
This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
Users who have discontinued the medication describe a sudden return of hunger.
"It was like a switch activating and I was suddenly extremely hungry," said a patient.
This challenge is worsened if patients have not developed permanent dietary or behavioural changes during treatment.
Growing Adoption
Survey data show that millions of adults in the UK have tried these injections in the last 12 months, with desire remaining high.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic fix and long-term success relies on ongoing lifestyle support.
